GSP Crop Science Limited has officially announced the outcome of its Board Meeting held on May 14, 2026, where the Board approved the acquisition of the remaining 21% equity stake in its subsidiary, GSP Intermediates Private Limited (GIPL). This strategic transaction involves the purchase of 31,50,000 equity shares at a price of Rs. 10 per share, totaling a cash consideration of Rs. 3.15 Crores. Upon completion of this acquisition, GIPL will become a wholly-owned subsidiary of GSP Crop Science Limited, further solidifying the company’s control over its manufacturing supply chain.

The acquisition is classified as a Related Party Transaction as GIPL was already a subsidiary, and it has been executed at “Arm’s Length” based on a valuation report from a registered valuer . GSP Intermediates Private Limited, incorporated in August 2022, specializes in manufacturing and processing agrochemical intermediates and allied products . For the financial year ending March 31, 2025, GIPL reported a turnover of Rs. 1.22 Crores, having recently commenced commercial production in the latter part of FY 2024-25 .

GSP Crop Science Limited is a prominent Indian agrochemical player established in 1985, focused on the manufacturing and distribution of insecticides, herbicides, fungicides, and plant growth regulators . In recent 2025 updates, the company has emphasized its strong research and development capabilities, holding 102 granted patents with another 108 in the pipeline as of late 2025 . The company recently launched a Rs. 400 Crore mainboard IPO in March 2026 to fund debt repayment and general corporate purposes, signaling a major phase of expansion .

For the full financial year 2024-25 (FY25), GSP Crop Science reported a robust performance with total revenue reaching Rs. 1,287.38 Crores and a Profit After Tax (PAT) of Rs. 83.44 Crores, representing a 36% year-on-year growth in profitability . In the third quarter ending December 31, 2025, the company recorded a consolidated total income of Rs. 270.35 Crores . Prominent institutional involvement was noted during its 2026 IPO, which saw participation from various Qualified Institutional Buyers (QIBs), and the company is backed by the Kappa Trust, which participated as a selling shareholder in the offer for sale .